CD25 Chimeric Antigen Receptor Patent Granted to Montefiore Medical Center
Summary
USPTO granted US Patent US12606630B2 to Montefiore Medical Center covering CD25 chimeric antigen receptors and their therapeutic uses. The patent, applied for in August 2020, contains 19 claims covering compositions and methods for immune enhancement and cancer treatment. This grant confers exclusive intellectual property rights to the assignee for the claimed biological compositions and treatment methods.
What changed
USPTO issued patent grant US12606630B2 to Montefiore Medical Center for CD25 chimeric antigen receptors and uses thereof. The patent covers CD25 CAR compositions, methods of treating subjects, methods of enhancing immune systems, and methods of killing target cells including cancer cells. The patent contains 19 claims and lists CPC classifications spanning therapeutic peptides, pharmaceutical compositions, and gene therapy vectors.
Affected parties seeking to develop, manufacture, or commercialize CD25-targeting chimeric antigen receptor technologies should conduct freedom-to-operate analyses and consider licensing negotiations with Montefiore Medical Center to avoid infringement of the granted claims.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD25 chimeric antigen receptors and uses thereof
Grant US12606630B2 Kind: B2 Apr 21, 2026
Assignee
MONTEFIORE MEDICAL CENTER
Inventors
Ira Braunschweig
Abstract
Provided herein are CD25 chimeric antigen receptors and compositions and methods for using the same. Methods for using CD25 chimeric antigen receptors provided herein include, for example, methods of treatment, methods of enhancing the immune system in a subject, and methods of killing a target cell or a population of target cells.
CPC Classifications
C07K 16/2866 C07K 14/55 C07K 14/7051 C07K 14/70517 C07K 14/70521 C07K 14/70578 C07K 2317/53 C07K 2319/02 C07K 2319/03 C07K 2319/33 C07K 2317/622 A61K 40/11 A61K 40/31 A61K 40/4224 A61K 38/00 A61K 2039/54 A61P 35/00 C12N 15/86 C12N 2740/10043 C12N 2740/15043
Filing Date
2020-08-28
Application No.
17753364
Claims
19
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.